<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The preventive effect of argatroban, a synthetic thrombin inhibitor, on <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> was evaluated with <z:chebi fb="1" ids="4775">ellagic acid</z:chebi> (EA)-induced cerebral <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> in rats </plain></SENT>
<SENT sid="1" pm="."><plain>Platelet-rich <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> containing fibrin and EA crystal were formed in the microarteries in the affected hemisphere by the injection of EA suspension into the cerebral arteries </plain></SENT>
<SENT sid="2" pm="."><plain>The mortality in saline control was over 80% 6 h after the EA injection </plain></SENT>
<SENT sid="3" pm="."><plain>Argatroban decreased the mortality to 0% at a dose of 3 mg/kg/h, and significantly reduced the ischemic area in the affected cerebral hemisphere </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="5" ids="28304">Heparin</z:chebi> also decreased the mortality to 30% at a dose of 600 U/kg/h, but marked <z:mp ids='MP_0001914'>bleeding</z:mp> was observed at the incised wound </plain></SENT>
<SENT sid="5" pm="."><plain>These findings suggest that argatroban is a more effective and safer <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> than <z:chebi fb="5" ids="28304">heparin</z:chebi> for the prevention of ischemic damage on <z:hpo ids='HP_0005305'>cerebral thrombosis</z:hpo> </plain></SENT>
</text></document>